Abstract 424P
Background
Paraneoplastic leucomoid reaction (PLR) is well described entity where white blood cell (WBC) count increase ≥50000/mm3 in association with malignancy.It is known to be predictive of poor prognosis.Recent research works have demonstrated that there are relationships between PLR activated by intratumoral production of granulocyte colony stimulatory factor (G-CSF), the RAS/RAF/MEK pathway and tumorogenesis. It may even seen before diagnosis of malignancy. It is too important to understand the cause of high WBC count to start specific proper treatment or change treatment protocol because many clinicians delayed to start treatment that harmful for patients.
Methods
The study was an observational study. Study period was January 2022 to June 2022.
Results
Of total 350 patients, PLR was found in only 24 (6.86%).Age range of patients were from 32 years to 85 years and average was 60 years. Among them, carcinoma lung 6(25%) where 4(66.66%) patients were metastatic to liver and 2(33.33%) patient had localized disease; carcinoma gall bladder 4(16.66%) where 4(100%) had metastasis to liver; carcinoma unknown primary 4(16.66%); carcinoma buccal mucosa 4(16.66%); carcinoma cervix 2(8.33%); metastatic prostate cancer 2(8.33%) and carcinoma urinary bladder 2(8.33%).Infections were ruled out methodically by culture and sensitivity of blood, urine, bone marrow but none showed any growth. 14(58.33%) patients were on specific treatment and 41.67%) patients were on supportive management after PLR develop. 23(95.83%) patients developed PLR after diagnosis of cancer or during cancer treatment or many days thereafter. Only 1(4.17%) patient developed PLR before diagnosis of malignancy. WBC count ≥50000/mm3 were found in 23(95.83%) and only 1(4.67%) patient had 45000/ mm3. Neutrophil count ≥90% were documented in 14(58.33%) patients and ≥85% in 10(41.67%). Platelet count were found high in 12(50%). Bone marrow examinations16(66.67%) showed Neutrophilic leucocytosis in 14(87.5%) patients.Death from development of PLR from 4 days to 240 days and average time of death was documented within 72 days.
Conclusions
In developing countries, patients were underwent investigations repeatedly for a long period for PLR that delayed diagnosis, ultimately delayed treatment and we lost patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Abdullah Al Mamun Khan.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
409P - Tertiary lymphoid structures are scarce but associated with BCR clonal expansion, B cell activity and checkpoint inhibitor response in advanced osteosarcoma
Presenter: Qiyuan Bao
Session: Poster viewing 06
410P - The incidence and risk factors of kidney injury in patients receiving immune checkpoint inhibitors: A retrospective observational cohort study
Presenter: Thanawat Suksomboon
Session: Poster viewing 06
411P - Cost-effective analysis of the various cancer screening methods in the community: Pooled analysis of camps of 5 years from 2017-to 2022
Presenter: Suresh Attili
Session: Poster viewing 06
412P - Substance-P in the blood is related with the efficacy of aprepitant for targeted drug-induced refractory pruritus in Chinese malignancy population
Presenter: Fang Gao
Session: Poster viewing 06
413P - Association of concomitant medications on survival outcomes in cancer patients treated with immune checkpoint inhibitors: Analysis of health insurance review and assessment database
Presenter: Soojung Hong
Session: Poster viewing 06
414P - Lessons learnt from clinico-genomic profiling of families with Li Fraumeni Syndrome: The largest case series from the Indian setting
Presenter: Ghazal Tansir
Session: Poster viewing 06
415P - Small cell lung cancer: Epidemiological patterns and mutational profile in the United States
Presenter: Abdallah Allam
Session: Poster viewing 06
416P - Survival outcomes predicted by irAEs on 18F-FDG-PET in response to PD-1 antibody therapy in metastatic melanoma
Presenter: Sarah Lewis
Session: Poster viewing 06
417P - The activity and safety of anlotinib for patients with recurrent malignant glioma: A single-center, retrospective study
Presenter: Xudong Sun
Session: Poster viewing 06
418P - Mutational landscape of non-small cell lung cancer in the United States
Presenter: Mostafa Elsayed
Session: Poster viewing 06